Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neose Technologies has received a milestone payment from Novo Nordisk, under a license agreement for the use of its GlycoPEGylation technology to develop a next-generation version of Factor IX.
Subscribe to our email newsletter
The company is also working with Novo Nordisk under separate license agreements to develop GlycoPEGylated versions of recombinant Factors VIIa and VIII. A Phase I trial of GlycoPEG-Factor VIIa is currently ongoing.
George Vergis, president and CEO of Neose, said: “We are excited about Novo Nordisk’s continued progress in developing a long-acting Factor IX using our GlycoPEGylation technology.”